Craft

NeoGenomics Laboratories

Stock Price

$13.5

2024-07-10

Market Capitalization

$1.7 B

2024-07-10

Revenue

$591.6 M

FY, 2023

NeoGenomics Laboratories Summary

Company Summary

Overview
NeoGenomics Laboratories is a company that operates a network of cancer-focused testing laboratories. It operates through Clinical Services and Pharma Services segments. The company provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations, and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, etc. NeoGenomics Laboratories caters to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Type
Public
Status
Active
Founded
2002
HQ
Fort Myers, FL, US | view all locations
Website
https://neogenomics.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Chris Smith

    Chris Smith, Chief Executive Officer

  • Maher Albitar

    Maher Albitar, Chief Medical Officer and Director of Research and Development

    • Douglas Brown

      Douglas Brown, Chief Strategy and Corporate Development Officer

      • John Mooney

        John Mooney, Chief Technology Officer

      Operating MetricsView all

      Facility Space, sq. ft.

      533.4K
      37.6%

      FY, 2021

      Testing Services

      6

      Q3, 2022

      Facility Space Owned (Corporate), sq.ft.

      43.6K

      Q3, 2022

      LocationsView all

      11 locations detected

      • Fort Myers, FL HQ

        United States

        9490 NeoGenomics Way

      • Aliso Viejo, CA

        United States

        31 Columbia

      • Atlanta, GA

        United States

        2800 Century Pkwy NE, Suite 250

      • Carlsbad, CA

        United States

        2173 Salk Ave #300

      • Fort Myers, FL

        United States

        12701 Commonwealth Dr., Suite 9

      • Houston, TX

        United States

        7256 South Sam Houston Parkway West, #300

      and 5 others

      NeoGenomics Laboratories Financials

      Summary Financials

      Revenue (Q1, 2024)
      $156.2M
      Gross profit (Q1, 2024)
      $65.5M
      Net income (Q1, 2024)
      ($27.1M)
      Cash (Q1, 2024)
      $331.9M
      EBIT (Q1, 2024)
      ($30.6M)
      Enterprise value
      $1.9B

      Footer menu